Paying for Mental Health Care

Insurance Coverage for Spravato: Who Qualifies

Save

Many plans cover Spravato, but conditionally. Insurers generally follow the FDA-approved treatment-resistant-depression use, expect it to be paired with an oral antidepressant, and require dosing at a certified center. Meeting those criteria makes coverage likely, and a denial carries appeal rights you can use.

Last updated: July 2026

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

Continue in Claude

Open a chat with this article’s link already in the message, and keep asking questions there. Claude reads the article and its sources; nothing about you is included.

Continue in Claude →

The button opens the Claude desktop app and fills in the message for you to review before sending. No desktop app, or reading on a phone? Copy the prompt and paste it into any AI.

Screening tool

PHQ-9

A validated, public-domain questionnaire that measures depression symptoms over the last two weeks — a screen, not a diagnosis, validated for adults 18 and older. 9 questions · about 3 minutes.

Take the 3-minute PHQ-9 depression screening →

Synthetic demonstration content. If you need help now: call or text 988, or text HOME to 741741. If you are in immediate danger, call 911.

Does insurance cover Spravato at all?

For a lot of people, yes — but coverage comes with conditions, and understanding them is what separates an approval from a denial. Spravato is an FDA-approved esketamine treatment for treatment-resistant depression, and insurers generally build their coverage around that approved use 1. That framing matters: because it is a formally approved therapy rather than an experimental one, plans have a basis to pay when the criteria are met. Real-world claims data confirm that a meaningful share of patients access esketamine through their benefits rather than paying cash 3. The practical question is therefore not whether Spravato can be covered, but whether your situation fits the specific rules your plan uses to say yes.

What does "treatment-resistant" have to mean?

The central criterion is the diagnosis. Coverage is written for treatment-resistant depression, which generally means major depression that has not responded adequately to prior antidepressant treatment. In practice, plans look for documentation that you have tried antidepressant medications without sufficient relief — the same trial history that supports other advanced options. Cost-effectiveness analyses evaluate esketamine precisely in this treatment-resistant population, which is why plans anchor eligibility there 2. If your chart already reflects that history, you likely meet the core requirement; if it does not, the gap is usually documentation rather than a permanent bar. Seeing how to assemble the qualification checklist helps you check your record against the rule before you apply.

Why do plans expect an oral antidepressant too?

Spravato was studied and approved for use alongside an oral antidepressant, not as a standalone treatment, and the cost-effectiveness research plans rely on models that same combination 2. As a result, many plans expect your record to show that Spravato is being added to an oral antidepressant rather than replacing all other treatment. This is not a hoop for its own sake — it reflects how the therapy was tested and labeled. If you and your prescriber are already planning the treatment this way, the requirement is usually met without extra effort. If a plan cites the oral-antidepressant pairing in a denial, that is a concrete, addressable point your prescriber can document rather than a vague rejection.

What about the certified-center requirement?

Coverage almost always assumes the drug is administered at an approved site. Because Spravato can only be dispensed and given at certified centers under a federal safety program, plans expect the claim to come from one, and receiving it elsewhere is generally not an option. That constraint shapes access as much as the clinical criteria do: your covered choices are the certified clinics your plan works with. If your closest certified center is out of network, it is worth asking the plan how it handles that, since network and site rules can interact. Confirming both your diagnosis criteria and an in-network certified site before you start prevents the two most common coverage surprises.

When a denial is worth appealing

A first "no" on Spravato is often a fixable coverage decision rather than a final answer. If your plan denies it, you generally have the right to an internal appeal and then an independent external review 4. Denials frequently rest on a specific, nameable gap — missing documentation of prior antidepressant trials, the oral-antidepressant pairing, or the treatment-resistant diagnosis language — and your prescriber can often supply exactly that. Asking the plan which criterion it cited tells you what the appeal must address. If you use Gale to work with a provider, you can make sure the record is complete before the first submission, which is usually easier than fighting a denial after the fact. Medicaid coverage of Spravato follows its own state-by-state fine print worth checking separately.

Common questions

Many plans do, but only when the criteria are met — generally a treatment-resistant depression diagnosis, use alongside an oral antidepressant, and dosing at a certified center 12. Whether your specific situation qualifies depends on your documented treatment history and your plan's policy, which the clinic's billing office can help you confirm before you start.

Plans generally mean major depression that has not responded adequately to prior antidepressant treatment, shown through documented medication trials that did not provide enough relief 2. If your chart already reflects that history, you likely meet the core requirement; if not, the issue is usually missing documentation rather than a permanent disqualification.

Spravato was approved for use alongside an oral antidepressant rather than on its own, and many plans expect your record to reflect that pairing 2. If a denial cites this point, it is a specific, addressable item your prescriber can document. The exact expectation varies by plan, so confirming it in advance is worthwhile.

A denial is a coverage decision with appeal rights — an internal appeal, then an independent external review 4. Denials often rest on a nameable gap like missing trial documentation or the oral-antidepressant pairing, which your prescriber can frequently supply. Asking which criterion the plan cited tells you what the appeal needs to fix.

Related

Say it back

How would you explain this to someone you love?

Two or three sentences, just as you’d say it. Gale reflects back what you focused on — a mirror, not a quiz.

If things feel heavy, a person is available anytime — call or text 988.

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

If depression is urgent while coverage is pending

  • —Thoughts of suicide, or of not wanting to be alive
  • —Symptoms worsening while an authorization or appeal is in progress
  • —Delaying all care until the Spravato coverage question is resolved

Spravato coverage criteria vary by health plan and by state Medicaid program; this article describes general patterns, not your specific policy or medical situation. It is general information, not medical or insurance advice. If you are in crisis, call or text 988 (Suicide & Crisis Lifeline), free and available 24/7.

References

  1. 1.Agboola F et al. (2020). The Effectiveness and Value of Esketamine for the Management of Treatment-Resistant Depression. Journal of Managed Care & Specialty Pharmacy (JMCP). doi:10.18553/jmcp.2020.26.1.16 ✓esketamine-cost-effectivenessesketamine-value-assessmenticer-reporttreatment-resistant-depression-cost
  2. 2.Ross EL & Soeteman DI (2020). Cost-Effectiveness of Esketamine Nasal Spray for Patients With Treatment-Resistant Depression in the United States. Psychiatric Services. doi:10.1176/appi.ps.201900625 ✓esketamine-cost-effectivenessspravato-accesstreatment-resistant-depression-cost
  3. 3.Zhdanava M et al. (2023). Esketamine nasal spray for major depressive disorder with acute suicidal ideation or behavior: description of treatment access, utilization, and claims-based outcomes in the United States. Journal of Medical Economics. doi:10.1080/13696998.2023.2208993 ✓esketamine-coveragespravato-accessclaims-based-utilizationinterventional-access
  4. 4.U.S. Centers for Medicare & Medicaid Services / HealthCare.gov (2025). How to Appeal an Insurance Company Decision. HealthCare.gov. link ✓appeal-denied-claiminternal-appealexternal-reviewcoverage-denial

4 sources, numbered by first appearance. General health information, not medical advice. AI-assisted editorial content — every citation independently verified. Editorial policy

← Back to the health library